ATE277927T1 - Aryl- und heteroaryl-kondensierte aminoalkyl- imidazol-derivate: selektive modulatoren der gabaa-rezeptoren - Google Patents
Aryl- und heteroaryl-kondensierte aminoalkyl- imidazol-derivate: selektive modulatoren der gabaa-rezeptorenInfo
- Publication number
- ATE277927T1 ATE277927T1 AT00919975T AT00919975T ATE277927T1 AT E277927 T1 ATE277927 T1 AT E277927T1 AT 00919975 T AT00919975 T AT 00919975T AT 00919975 T AT00919975 T AT 00919975T AT E277927 T1 ATE277927 T1 AT E277927T1
- Authority
- AT
- Austria
- Prior art keywords
- sub
- aryl
- imidazole derivatives
- gabaa receptors
- selective modulators
- Prior art date
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 1
- 102000027484 GABAA receptors Human genes 0.000 title 1
- 108091008681 GABAA receptors Proteins 0.000 title 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title 1
- 239000000556 agonist Substances 0.000 abstract 4
- 239000005557 antagonist Substances 0.000 abstract 2
- 210000004556 brain Anatomy 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 230000036626 alertness Effects 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 229940049706 benzodiazepine Drugs 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12752699P | 1999-04-02 | 1999-04-02 | |
| US28535799A | 1999-04-02 | 1999-04-02 | |
| PCT/US2000/008610 WO2000059905A1 (en) | 1999-04-02 | 2000-03-31 | ARYL AND HETEROARYL FUSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAa RECEPTORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE277927T1 true ATE277927T1 (de) | 2004-10-15 |
Family
ID=26825721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00919975T ATE277927T1 (de) | 1999-04-02 | 2000-03-31 | Aryl- und heteroaryl-kondensierte aminoalkyl- imidazol-derivate: selektive modulatoren der gabaa-rezeptoren |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7348326B2 (de) |
| EP (1) | EP1165557B1 (de) |
| JP (1) | JP2002541151A (de) |
| AT (1) | ATE277927T1 (de) |
| AU (1) | AU4058000A (de) |
| BR (1) | BR0009539A (de) |
| CA (1) | CA2369557A1 (de) |
| DE (1) | DE60014339T8 (de) |
| ES (1) | ES2226812T3 (de) |
| MX (1) | MXPA01009949A (de) |
| WO (1) | WO2000059905A1 (de) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6281237B1 (en) | 1999-04-02 | 2001-08-28 | Neurogen Corporation | N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives |
| AU4055300A (en) * | 1999-04-02 | 2000-10-23 | Neurogen Corporation | Aryl and heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of Bradykinin B2 receptors |
| MXPA03003039A (es) * | 2000-10-06 | 2003-10-15 | Neurogen Corp | Derivados de indola y bencimidazola como moduladores del receptor crf. |
| PA8535601A1 (es) | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
| WO2003059289A2 (en) | 2002-01-10 | 2003-07-24 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues |
| PE20040804A1 (es) * | 2002-12-19 | 2004-12-31 | Boehringer Ingelheim Pharma | DERIVADOS DE CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa |
| EP1594848A1 (de) * | 2003-02-19 | 2005-11-16 | Neurogen Corporation | Arylsäurepyrimidinylmethylamide, -pyridazinylmethylamide undverwandte verbindungen |
| ES2222813B1 (es) * | 2003-07-24 | 2005-12-16 | Ferrer Internacional, S.A. | N-(3-(3-sustituidas-pirazolo(1,5-a)pirimidin-7-il)-fenil)-sulfonamidas y composiciones y metodos relacionados. |
| BRPI0412908A (pt) * | 2003-07-25 | 2006-09-26 | Neurogen Corp | composto ou um sal deste farmaceuticamente aceitável, composição farmacêutica, métodos para o tratamento de ansiedade, depressão, um distúrbio do sono, distúrbio de déficit de atenção ou demência de alzheimer, para potenciar um efeito terapêutico de um agente do cns, para melhorar a memória de curta duração em um paciente, para alterar a atividade de transdução de sinal de receptor gabaa, e para determinar a presença ou ausência de receptor gabaa em uma amostra, preparação farmacêutica acondicionada, e, uso de um composto ou sal |
| JP4869072B2 (ja) * | 2003-11-14 | 2012-02-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｐ結合カセットトランスポーターのモジュレーターとして有用なチアゾールおよびオキサゾール |
| US7271271B2 (en) | 2004-06-28 | 2007-09-18 | Amgen Sf, Llc | Imidazolo-related compounds, compositions and methods for their use |
| US8815881B2 (en) * | 2010-08-09 | 2014-08-26 | Hoffmann-La Roche Inc. | 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds |
| MY170236A (en) | 2010-10-06 | 2019-07-11 | Glaxosmithkline Llc | Benzimidazole derivatives as pi3 kinase inhibitors |
| US20150374705A1 (en) | 2012-02-14 | 2015-12-31 | Shanghai Institues for Biological Sciences | Substances for treatment or relief of pain |
| AR095883A1 (es) * | 2013-04-18 | 2015-11-18 | Astellas Pharma Inc | Compuestos de acetamida heterocíclica |
| WO2017087885A1 (en) | 2015-11-19 | 2017-05-26 | Dana-Farber Cancer Institute, Inc. | Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers |
| US11497752B2 (en) | 2018-01-30 | 2022-11-15 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2020081588A1 (en) | 2018-10-17 | 2020-04-23 | Dana-Farber Cancer Institute, Inc. | Swi/snf family chromatin remodeling complexes and uses thereof |
| US12384776B2 (en) | 2019-01-29 | 2025-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US12509453B2 (en) | 2019-01-29 | 2025-12-30 | Foghorn Therapeutics Inc. | BRM/BRG1 inhibitors and uses thereof |
| AU2021213811A1 (en) | 2020-01-29 | 2022-07-28 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2021155264A1 (en) * | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| US12606553B2 (en) | 2021-03-09 | 2026-04-21 | Foghorn Therapeutics Inc. | Crystalline forms, compositions containing same, and methods of their use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5527819A (en) * | 1991-09-06 | 1996-06-18 | Merck & Co., Inc. | Inhibitors of HIV reverse transcriptase |
| AU675484B2 (en) * | 1993-03-24 | 1997-02-06 | Neurosearch A/S | Benzimidazole compounds, their use and preparation |
| NZ290008A (en) * | 1994-06-29 | 1998-08-26 | Smithkline Beecham Corp | Vitronectin receptor antagonists, comprising a fibrinogen antagonist analogue linked to a heterocycle |
| PL183853B1 (pl) * | 1995-04-21 | 2002-07-31 | Neurosearch As | Nowa pochodna benzimidazolu i środek farmaceutyczny |
| IL125033A0 (en) * | 1995-12-29 | 1999-01-26 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
| WO1998017651A1 (en) * | 1996-10-21 | 1998-04-30 | Neurosearch A/S | 1-phenyl-benzimidazole compounds and their use as baga-a receptor modulators |
| US6380210B1 (en) * | 1999-04-02 | 2002-04-30 | Neurogen Corporation | Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors |
-
2000
- 2000-03-31 WO PCT/US2000/008610 patent/WO2000059905A1/en not_active Ceased
- 2000-03-31 JP JP2000609416A patent/JP2002541151A/ja not_active Withdrawn
- 2000-03-31 DE DE60014339T patent/DE60014339T8/de not_active Expired - Fee Related
- 2000-03-31 CA CA002369557A patent/CA2369557A1/en not_active Abandoned
- 2000-03-31 BR BRPI0009539-7A patent/BR0009539A/pt not_active Application Discontinuation
- 2000-03-31 ES ES00919975T patent/ES2226812T3/es not_active Expired - Lifetime
- 2000-03-31 MX MXPA01009949A patent/MXPA01009949A/es active IP Right Grant
- 2000-03-31 AU AU40580/00A patent/AU4058000A/en not_active Abandoned
- 2000-03-31 AT AT00919975T patent/ATE277927T1/de not_active IP Right Cessation
- 2000-03-31 EP EP00919975A patent/EP1165557B1/de not_active Expired - Lifetime
-
2005
- 2005-12-06 US US11/295,173 patent/US7348326B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| BR0009539A (pt) | 2006-06-06 |
| MXPA01009949A (es) | 2003-07-14 |
| WO2000059905A1 (en) | 2000-10-12 |
| EP1165557A1 (de) | 2002-01-02 |
| DE60014339T2 (de) | 2006-02-09 |
| ES2226812T3 (es) | 2005-04-01 |
| AU4058000A (en) | 2000-10-23 |
| US7348326B2 (en) | 2008-03-25 |
| CA2369557A1 (en) | 2000-10-12 |
| US20060160842A1 (en) | 2006-07-20 |
| DE60014339D1 (de) | 2004-11-04 |
| DE60014339T8 (de) | 2006-04-27 |
| EP1165557B1 (de) | 2004-09-29 |
| JP2002541151A (ja) | 2002-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE277927T1 (de) | Aryl- und heteroaryl-kondensierte aminoalkyl- imidazol-derivate: selektive modulatoren der gabaa-rezeptoren | |
| ATE289593T1 (de) | Substituierte 4-oxo-chinolin-3-carboxamide als gaba gehirnrezeptorliganden | |
| DK0555391T3 (da) | Visse imidazoquinoxaliner; en ny klasse GABA-receptorligander i hjernen | |
| DE60114227D1 (de) | 2,4-substituierte pyridinderivate | |
| CA2175204A1 (en) | Certain Fused Pyrrolecarboxanilides; a New Class of GABA Brain Receptor Ligands | |
| PT1147110E (pt) | Derivados de pirazino (aza)-indol | |
| NZ330861A (en) | Fused pyrrolecarboxamides and use as a new class of GABA brain receptor ligands | |
| WO2002000623A3 (en) | Aryl fused substituted 4-oxy-pyridines | |
| CY1106645T1 (el) | Παραγωγα 1,2,4 τριαμινοβενζολης χρησιμα για τη θεραπευτικη αντιμετωπιση διαταραχων του κεντρικου νευρικου συστηματος | |
| BR9106665A (pt) | Derivados de quinuclidina | |
| ATE435010T1 (de) | Verwendung von retinoid rezeptor antagonisten für die behandlung von knochen und knorpel pathologien | |
| BR9908321A (pt) | Composto | |
| ATE247639T1 (de) | Arylsubstituierte cyclische amine als selektive dopamin-d3-liganden | |
| ATE304530T1 (de) | Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen | |
| CA2301599A1 (en) | Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands | |
| ATE236134T1 (de) | Isoquinolinamin und phtalazinamin derivate, die reagieren mit crf rezeptoren | |
| DE69925160D1 (de) | Arylpiperidin- und aryl-1,2,5,6-tetrahydropyridinamid-derivate mit 5ht1a rezeptor aktivität | |
| EP1172106A3 (de) | Werwendung von fluoralkoxybenzylaminoderivate stickstoffhaltiger heterocyclen als substanz p antagonisten | |
| DE69926378D1 (de) | Oxo-pyridoimidazol-carboxamide: gaba-rezeptor-liganden im gehirn | |
| NO20012538D0 (no) | Anvendelse av N-substituerte azabicycloalkanderivater for behandling av forstyrrelser i sentralnervesystemet | |
| MY107732A (en) | Certain imidazoquinoxalines; a new class of gaba brain receptor ligands. | |
| CA2249562A1 (en) | Certain fused pyrrolecarboxamides as gaba brain receptor ligands | |
| MX9709771A (es) | Nuevas aril y cicloalquil imidazolonas substituidas, una clase de ligandos receptores de acido gamma-aminobutirico del cerebro. | |
| YU35292A (sh) | Izvesni imidazohinoksalini nova klasa gaba moždanih receptorskih liganada | |
| BG96204A (bg) | Имидазохиноксалини,нов клас gава лиганди на мозъчни рецептори |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |